Archive

Final Results for the year ended 30 June 2014

Chairman’s Statement   Summary of Results in the year ended 30 June 2014   The turnover of the Company increased by 12% to £267,903 (2013:…

Disclosure of Large Pharma partner Merck & Co.

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is delighted to announce that Merck & Co., a top 5 pharmaceutical company, has…

Meet The Industry Day

David Fell will give a presentation entitled “Physiomics: Predicting Optimal Therapeutic Strategies for the Pharmaceutical Industry”  Read more…

Update: 4th extension project to advance oncology candidate with global pharma company

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed a further extension to a Virtual…

EasyAP presented at the Safety Pharmacology Society 2014

Dr Eric Fernandez will present EasyAP at the Safety Pharmacology Society Meeting in Washington, DC, from the 19th to 22nd of October.

EasyAP Cardiotox Platform Launch

Physiomics is pleased to announce that it has now launched its predictive web-based platform for cardiac toxicity. EasyAP™ provides cardiac action potential time course simulations to…

EPIC Biotech conference

Dr Mark Chadwick will be attending this conference in London, UK Please click here for link to website…

ACI’s Cancer Drug Discovery & Preclinical Development conference

Dr Eric Fernandez will present on Virtual Tumour technology at the ACI’s Cancer Drug Discovery & Preclinical Development conference in London, UK, which is taking…

New deal to model immune therapy for cancer with global biopharmaceutical company

Physiomics is pleased to announce that it has signed a new contract with a global pharmaceutical company. The project will involve adapting the existing Virtual…

Physiomics enters the personalized medicine market. Anticipated new collaboration with Diatech Pharmacogenetics.

Physiomics is pleased to announce that it has signed a Heads of Terms agreement with Diatech Pharmacogenetics to negotiate a Collaboration Agreement. Under the terms…